Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the biotechnology company said Tuesday.
Multiple sclerosis is an autoimmune condition of the central nervous system.